U.S. markets open in 6 hours 49 minutes
  • S&P Futures

    3,644.75
    -16.25 (-0.44%)
     
  • Dow Futures

    29,105.00
    -98.00 (-0.34%)
     
  • Nasdaq Futures

    11,251.75
    -82.00 (-0.72%)
     
  • Russell 2000 Futures

    1,662.80
    -5.60 (-0.34%)
     
  • Crude Oil

    77.41
    -1.09 (-1.39%)
     
  • Gold

    1,628.40
    -7.80 (-0.48%)
     
  • Silver

    18.07
    -0.27 (-1.48%)
     
  • EUR/USD

    0.9564
    -0.0034 (-0.35%)
     
  • 10-Yr Bond

    3.9640
    0.0000 (0.00%)
     
  • Vix

    32.60
    +0.34 (+1.05%)
     
  • GBP/USD

    1.0671
    -0.0060 (-0.56%)
     
  • USD/JPY

    144.7330
    -0.0580 (-0.04%)
     
  • BTC-USD

    18,778.19
    -1,452.94 (-7.18%)
     
  • CMC Crypto 200

    429.67
    -29.47 (-6.42%)
     
  • FTSE 100

    6,984.59
    -36.36 (-0.52%)
     
  • Nikkei 225

    26,173.98
    -397.89 (-1.50%)
     

The Independent Director of Accelerate Diagnostics, Inc. (NASDAQ:AXDX), Jack Schuler, Just Bought 5.8% More Shares

·3 min read

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) shareholders (or potential shareholders) will be happy to see that the Independent Director, Jack Schuler, recently bought a whopping US$5.0m worth of stock, at a price of US$5.00. While that only increased their holding size by 5.8%, it is still a big swing by our standards.

Check out our latest analysis for Accelerate Diagnostics

The Last 12 Months Of Insider Transactions At Accelerate Diagnostics

Notably, that recent purchase by Jack Schuler is the biggest insider purchase of Accelerate Diagnostics shares that we've seen in the last year. That means that an insider was happy to buy shares at around the current price of US$5.00. Of course they may have changed their mind. But this suggests they are optimistic. We do always like to see insider buying, but it is worth noting if those purchases were made at well below today's share price, as the discount to value may have narrowed with the rising price. Happily, the Accelerate Diagnostics insiders decided to buy shares at close to current prices.

In the last twelve months Accelerate Diagnostics insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

Accelerate Diagnostics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Accelerate Diagnostics insiders own 40% of the company, currently worth about US$132m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.

So What Do The Accelerate Diagnostics Insider Transactions Indicate?

It's certainly positive to see the recent insider purchases. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Accelerate Diagnostics. That's what I like to see! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Accelerate Diagnostics. Every company has risks, and we've spotted 6 warning signs for Accelerate Diagnostics (of which 2 shouldn't be ignored!) you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.